Recent Updates
Recently added Catalysts

LY4006896

Phase 1

Parkinson Disease | Small molecule | Neurology |Eli Lilly and Company|Last Updated: Apr 20, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedCONTROLLEDBiomarker
Total Trials1
Total Enrollment127
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06809400A Study of LY4006896 in Healthy Participants and Participants With Parkinson's DiseasePHASE1 RECRUITING 127 — — Feb 18, 2025Jan 1, 2028Apr 20, 202614 United States, Japan
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Part A
Baseline to Week 48
Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs) Part A
Baseline to Week 48
Number of Participants with One or More SAEs Part B
Baseline to Week 61
Number of Participants with One or More TEAEs Part B
Baseline to Week 61
Secondary Endpoints
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4006896 ARC-Associated Antisense Part A
Baseline to Week 48
PK: Cmax of LY4006896 ARC-Associated Antisense Part B
Baseline to Week 61
PK: Area Under the Concentration versus Time Curve (AUC) of LY4006896 ARC-Associated Antisense Part A
Baseline to Week 48
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingSINGLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Part A LY4006896 + PlaceboEXPERIMENTALHealthy participants will receive a single escalating dose of LY4006896 and matching placebo.
Part B LY4006896 + PlaceboEXPERIMENTALParticipants with Parkinson's disease will receive multiple escalating doses of LY4006896 and matching placebo.
Interventions
NameTypeDescription
LY4006896DRUGAdministered intravenously (IV)
PlaceboDRUGAdministered IV
Unlock Study Design Details
Eligibility Criteria
Age Range30 Years — 85 Years
SexALL
Healthy VolunteersYes
Study Sites14

Inclusion Criteria: Part A Single Ascending Dose (SAD) and B Multiple Ascending Dose (MAD) * Have a body mass index within the range of 18 to 34 kilogram/square meter (kg/m²) (inclusive). * For Japanese participants: To qualify as a participant of first-generation Japanese origin, the participant,...

Countries:United StatesJapan
Unlock Eligibility Criteria
Competitive Landscape -Parkinson's Disease 59 trials
CompanyTickerTrialsLead PhaseDrugs
Supernus Pharmaceuticals, Inc.SUPN2PHASE3apomorphine infusion
Prothena Corp. PlcPRTA3PHASE3Prasinezumab, RO7046015
Biohaven Ltd.BHVN1PHASE2BHV-8000
Denali Therapeutics Inc.DNLI1PHASE2BIIB122
AC Immune SAACIU2PHASE2ACI-7104.056 at Dose A, ACI-7104.056 at Dose B, ACI-7104.056 at Dose C
Gain Therapeutics, Inc.GANX2PHASE2Low Dose GT-02287, GT-02287
BioVie Inc. Class ABIVI1PHASE2NE3107
Eli Lilly and CompanyLLY3PHASE1LY3884961, Methylprednisolone, Sirolimus, LY4006896, LY3962681
Annovis Bio IncANVS1PHASE2buntanetap/posiphen
Regeneron Pharmaceuticals, Inc.REGN2PHASE1ALN-SNCA
QIAGEN NVQGEN1PHASE2NEU-411
AbbVie, Inc.ABBV9 — Undisclosed
Illumina, Inc.ILMN1PHASE218F-MFBG
Masimo CorporationMASI1PHASE1Diprivan , Astra-Zeneca
MeiraGTx Holdings PlcMGTX1PHASE1AAV-GAD
Boston Scientific CorporationBSX3 — Undisclosed
Serina TherapeuticsSER1PHASE1SER-252
Abbott LaboratoriesABT2NAUndisclosed
Ardelyx, Inc.ARDX1PHASE2Tenapanor
Novo Nordisk A/S Sponsored ADR Class BNVO1 — Undisclosed
Unlock Competitive Intelligence
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT06809400primaryCompletionDate: changed
LOWMay 24, 2026NCT06809400studyFirstPostDate: changed